Anzeige
Mehr »
Login
Dienstag, 18.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Breaking News! Innocan Pharma - LPD-Humanversuche im Visier!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H80W ISIN: CH0100191136 Ticker-Symbol: V6MS 
Berlin
28.06.19
20:00 Uhr
0,000 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
RELIEF THERAPEUTICS HOLDING AG Chart 1 Jahr
5-Tage-Chart
RELIEF THERAPEUTICS HOLDING AG 5-Tage-Chart

Aktuelle News zur RELIEF THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrRelief Therapeutics says its partnership with NRx is active despite lawsuit23
RELIEF THERAPEUTICS Aktie jetzt für 0€ handeln
FrEQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit3.341EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Legal Matter Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit 14-Jan-2022 / 07:00...
► Artikel lesen
DoNRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights14
DoNRx Pharma files counterclaim against Relief Therapeutics over Zyesami rights32
MiRosenkrieg bei Relief Therapeutics und NeuroRx eskaliert: Die an der Schweizer Börse SIX notierte ...48
MiEQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Comments on Lawsuit Filed Against It by NeuroRx2.275EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Legal Matter Relief Comments on Lawsuit Filed Against It by NeuroRx 12-Jan-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant...
► Artikel lesen
06.01.EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies5.105EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Regulatory Admission Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of...
► Artikel lesen
05.01.RLFTF Stock Alert: What Is Going on With Relief Therapeutics Today?40
05.01.EQS-News: RELIEF THERAPEUTICS Holding AG: Relief Therapeutics to Participate in Virtual Investor Conferences in January392EQS-News: RELIEF THERAPEUTICS Holding AG / Key word(s): Conference Relief Therapeutics to Participate in Virtual Investor Conferences in January 05.01.2022 / 07:00 Relief Therapeutics...
► Artikel lesen
04.01.EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use5.917EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Patent Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions...
► Artikel lesen
03.01.Relief Therapeutics-Partner NRx beantragt Patent in USA für Corona-Mittel Aviptadil467Genf (awp) - Der US-Partner von Relief Therapeutics hat in den USA ein Patent für die Wirkstoffzusammensetzung von Aviptadil angemeldet. Das vasoaktive intestinale Peptid (VIP) soll zur Herstellung...
► Artikel lesen
03.01.Biotech - Relief Therapeutics beruft ausserordentliche Generalversammlung ein21
03.01.Relief Therapeutics beruft ausserordentliche Generalversammlung ein337Dabei wird unter anderem Michelle Lock zur Zuwahl in den Verwaltungsrat vorgeschlagen. Ausserdem sollen das Vergütungsreglement für das Gremium angepasst und verschiedene Passagen der Statuten überarbeitet...
► Artikel lesen
03.01.EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA5.695EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): AGMEGM Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA 03-Jan-2022 / 07:00 CET/CEST Release...
► Artikel lesen
30.12.21EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies3.704EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Miscellaneous Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of...
► Artikel lesen
28.12.21EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'3.724EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Patent Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide...
► Artikel lesen
16.12.21Relief Therapeutics files Form 20-F with the SEC37
16.12.21EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission1.604EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Miscellaneous Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission 16-Dec-2021...
► Artikel lesen
15.12.21EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-192.027EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Study results Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b...
► Artikel lesen
10.12.21Relief Therapeutics-Partner NRx einigt sich auf Entwicklungspfad für Aviptadil in Ungarn561Genf (awp) - Der US-Partner des Biotechunternehmen Relief Therapeutics hat sich mit den ungarischen Gesundheitsbehörden auf einen Zulassungspfad für die Notfallanwendung des potentiellen Covid-Mittels...
► Artikel lesen
Seite:  Weiter >>
181 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,20